SAN

80.23

-0.12%↓

UCB

274.7

+1.85%↑

SHL.DE

37.73

+1.13%↑

ARGX

680.8

+1.01%↑

VIE

34.99

+0.52%↑

SAN

80.23

-0.12%↓

UCB

274.7

+1.85%↑

SHL.DE

37.73

+1.13%↑

ARGX

680.8

+1.01%↑

VIE

34.99

+0.52%↑

SAN

80.23

-0.12%↓

UCB

274.7

+1.85%↑

SHL.DE

37.73

+1.13%↑

ARGX

680.8

+1.01%↑

VIE

34.99

+0.52%↑

SAN

80.23

-0.12%↓

UCB

274.7

+1.85%↑

SHL.DE

37.73

+1.13%↑

ARGX

680.8

+1.01%↑

VIE

34.99

+0.52%↑

SAN

80.23

-0.12%↓

UCB

274.7

+1.85%↑

SHL.DE

37.73

+1.13%↑

ARGX

680.8

+1.01%↑

VIE

34.99

+0.52%↑

Search

Laboratorios Farmaceuticos Rovi SA

Fechado

SetorSaúde

83.45 1.27

Visão Geral

Variação de preço das ações

24h

Atual

Mín

83.3

Máximo

83.5

Indicadores-chave

By Trading Economics

Rendimento

-33M

43M

Vendas

7.9M

218M

P/E

Médio do Setor

34.873

66.418

EPS

0.834

Margem de lucro

19.539

Funcionários

1,950

EBITDA

-21M

63M

Recomendações

By TipRanks

Recomendações

Comprar

Previsão para 12 meses

+4.08% upside

Dividendos

By Dow Jones

Próximos Ganhos

6 de mai. de 2026

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

233M

4.2B

Abertura anterior

82.18

Fecho anterior

83.45

Sentimento de Notícias

By Acuity

50%

50%

156 / 348 Ranking em Healthcare

Pontuação Técnica

By Trading Central

Confiança

Weak Bullish Evidence

Laboratorios Farmaceuticos Rovi SA Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

10 de abr. de 2026, 17:04 UTC

Grandes Movimentos do Mercado

FDA Rejects Replimune's Melanoma Drug for a Second Time

11 de abr. de 2026, 09:30 UTC

Ganhos

After the Great EV Slowdown, High Gas Prices Are Tempting Americans Back -- WSJ

11 de abr. de 2026, 08:20 UTC

Conversa de Mercado

Energy & Utilities Roundup: Market Talk

11 de abr. de 2026, 08:20 UTC

Conversa de Mercado

Health Care Roundup: Market Talk

11 de abr. de 2026, 08:20 UTC

Conversa de Mercado
Notícias Principais

Basic Materials Roundup: Market Talk

11 de abr. de 2026, 00:00 UTC

Ganhos
Aquisições, Fusões, Aquisições de Empresas

Big Yachts, Big Bucks -- Barrons.com

10 de abr. de 2026, 21:55 UTC

Aquisições, Fusões, Aquisições de Empresas

Paramount Warrants Are an Underappreciated Aspect of Warner Bros. Deal -- Barrons.com

10 de abr. de 2026, 21:01 UTC

Ganhos

Cango Inc.: Files Annual Report on Form 20-F With SEC

10 de abr. de 2026, 20:50 UTC

Conversa de Mercado

Energy & Utilities Roundup: Market Talk

10 de abr. de 2026, 20:50 UTC

Conversa de Mercado
Notícias Principais

Basic Materials Roundup: Market Talk

10 de abr. de 2026, 20:50 UTC

Conversa de Mercado

Health Care Roundup: Market Talk

10 de abr. de 2026, 20:31 UTC

Conversa de Mercado

Convenience Store Traffic Slows as Gas Prices Rise -- Market Talk

10 de abr. de 2026, 20:10 UTC

Aquisições, Fusões, Aquisições de Empresas

This Women's Health Company Is Drawing Takeover Interest. The Stock Is Soaring. -- Barrons.com

10 de abr. de 2026, 19:15 UTC

Conversa de Mercado

Global Energy Roundup: Market Talk

10 de abr. de 2026, 19:15 UTC

Conversa de Mercado

Oil Futures Settle Lower With Focus on U.S.-Iran Talks -- Market Talk

10 de abr. de 2026, 19:08 UTC

Conversa de Mercado

Global Forex and Fixed Income Roundup: Market Talk

10 de abr. de 2026, 19:08 UTC

Conversa de Mercado

U.S. Natural Gas Futures End Week Lower -- Market Talk

10 de abr. de 2026, 18:38 UTC

Conversa de Mercado

Canada's Job Market Showing Soft Demand, Structural Decline in Supply -- Market Talk

10 de abr. de 2026, 18:25 UTC

Conversa de Mercado
Notícias Principais

Precious Metals Finish With Weekly Gains -- Market Talk

10 de abr. de 2026, 18:05 UTC

Conversa de Mercado

Rising Commodity Prices Seen Carrying More Weight Than Jobs Data for Bank of Canada Watchers -- Market Talk

10 de abr. de 2026, 17:31 UTC

Conversa de Mercado
Notícias Principais

U.S. Oil Rig Count Unchanged This Week At 411 -- Market Talk

10 de abr. de 2026, 17:26 UTC

Ganhos

Big Banks' Profits Set to Rise Even as 'Wall of Worry' Looms -- Barrons.com

10 de abr. de 2026, 17:10 UTC

Conversa de Mercado

White House Defense of Stablecoin Yields Is Welcome Move, Grayscale Says -- Market Talk

10 de abr. de 2026, 17:00 UTC

Notícias Principais

Construction Business Taking a Hit From Iran Conflict -- WSJ

10 de abr. de 2026, 16:20 UTC

Conversa de Mercado

Health Care Roundup: Market Talk

10 de abr. de 2026, 16:15 UTC

Conversa de Mercado

Global Commodities Roundup: Market Talk

10 de abr. de 2026, 16:12 UTC

Ganhos

Partners Group CEO: Group Well Positioned to Navigate Current Complex Environment

10 de abr. de 2026, 16:11 UTC

Ganhos

Partners Group: Traditional Programs Contributed $3.3B

10 de abr. de 2026, 16:10 UTC

Ganhos

Partners Group: $5B of New Commitments Came From Bespoke Solutions

10 de abr. de 2026, 16:10 UTC

Ganhos

Partners Group: That Is Across All Private Markets Asset Classes and Client Strategies

Comparação entre Pares

Variação de preço

Laboratorios Farmaceuticos Rovi SA Previsão

Preço-alvo

By TipRanks

4.08% parte superior

Previsão para 12 meses

Média 86.75 EUR  4.08%

Máximo 90 EUR

Mínimo 83.5 EUR

Com base em 2 analistas de Wall Street que oferecem metas de preço de 12 meses para Laboratorios Farmaceuticos Rovi SA - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Comprar

2 ratings

1

Comprar

1

Manter

0

Vender

Pontuação Técnica

By Trading Central

51.1 / N/ASuporte e Resistência

Curto Prazo

Weak Bullish Evidence

Médio Prazo

Strong Bullish Evidence

Longo Prazo

Weak Bearish Evidence

Sentimento

By Acuity

156 / 348 Ranking em Saúde

Sentimento de Notícias

Neutral

Volatilidade

Abaixo da média

Volume de Notícias (RCV)

Abaixo da média

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

$

Sobre Laboratorios Farmaceuticos Rovi SA

Laboratorios Farmaceuticos Rovi, S.A. engages in the research, development, manufacture, and marketing of pharmaceutical products in Spain and internationally. The company provides products for cardiology, osteoarticular/women's health, anesthesia /pain, diagnostic imaging contrast agents, central nervous system, urology, endocrinology, respiratory, and primary healthcare areas. Its principal products include Ameride, Bertanel, Bluxam, Enoxaparin Rovi, Calcium Vitamine D3 Rovi, Exxiv, Prinvil, Rhodogil, Glufan, Hibor, Hirobriz Breezhaler, Neparvis, Medicebran, Medikinet, Mysimba, Orvatez, Tryptizol, Ulunar Breezhaler, and Volutsa; and hospital products, such as Iomeron and Iopamiro, Multihance and Y Prohance, Sonovue, Empowercta+, Empowermr, and CT Express, Fibrilin, and Sodium Heparin Rovi. It also provides contract-manufacturing services to other companies for a range of pharmaceutical forms, including prefilled syringes, vials, suppositories, tablets, and sachets. Laboratorios Farmaceuticos Rovi, S.A. was incorporated in 1946 and is headquartered in Madrid, Spain. Laboratorios Farmaceúticos Rovi, S.A. is a subsidiary of Norbel Inversiones, S.L.
help-icon Live chat